<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522077</url>
  </required_header>
  <id_info>
    <org_study_id>17-132</org_study_id>
    <nct_id>NCT03522077</nct_id>
  </id_info>
  <brief_title>RAVE: Radial Artery Vascular Complication and Resource Utilization</brief_title>
  <official_title>RAVE: Radial Artery Vascular Complication and Resource Utilization in Subjects Undergoing an Angiogram/PCI (Percutaneous Coronary Intervention)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chitogen, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if there is a reduction in time to&#xD;
      hemostasis in subjects treated with SoftSeal®-STF hemostatic pad when used in conjunction&#xD;
      with a vascular compression device after radial transcatheter procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SoftSeal-STF hemostatic pad and compression devices (TR BAND® and RadAR EasyCLik)&#xD;
      function to stop bleeding without obstructing radial artery flow, and have been shown to&#xD;
      reduce the occurrence of radial artery occlusion.&#xD;
&#xD;
      The SoftSeal-STF hemostatic pad is an FDA-approved, chitosan-based, non-woven pad with a&#xD;
      unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like&#xD;
      synthetic clot. Its mechanism of action is believed to be due to bioadhesion between the&#xD;
      chitosan polymer chains, which are positively charged, and the negatively charged blood and&#xD;
      tissue components, thereby stopping bleeding.&#xD;
&#xD;
      In this study the RadAR EasyCLik and TR BAND® Compression devices will be used with the&#xD;
      SoftSeal®-STF hemostatic pad to promote hemostasis at the puncture site. Both vascular&#xD;
      compression devices are FDA approved.&#xD;
&#xD;
      The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of&#xD;
      arterial, venous and hemodialysis percutaneous access sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>1 day</time_frame>
    <description>Time interval in minutes beginning with sheath removal and ending with removal of hemostatic device and/or observed hemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute radial artery occlusion</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects who experience radial artery occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major access site bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>A ≥ 3 mg/dL drop in hemoglobin, or required blood transfusion or vascular repair to control bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor access site bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>Light bleeding without hematoma formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor access site bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Light bleeding without hematoma formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma formation</measure>
    <time_frame>1 day</time_frame>
    <description>≥ 3 cm in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Pain at access site on numeric scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>30 days</time_frame>
    <description>Pain at access site on numeric scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of hand/digit ischemia</measure>
    <time_frame>1 day</time_frame>
    <description>Pain, tingling, or numbness in the hand and/or fingers reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of hand/digit ischemia</measure>
    <time_frame>30 days</time_frame>
    <description>Pain, tingling, or numbness in the hand and/or fingers reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>30 days</time_frame>
    <description>Vascular complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bruising, swelling, or redness</measure>
    <time_frame>30 days</time_frame>
    <description>At or near access site</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Angiogram</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>RadAR EasyCLik plus SoftSeal®-STF hemostatic pad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (&lt; 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TR BAND® plus SoftSeal®-STF hemostatic pad</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (&lt; 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoftSeal®-STF hemostatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (&lt; 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VascBand™ Hemostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RadAR EasyCLik plus ®-STF hemostatic pad</intervention_name>
    <description>Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device</description>
    <arm_group_label>RadAR EasyCLik plus SoftSeal®-STF hemostatic pad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TR BAND® Compression device plus ®-STF hemostatic pad</intervention_name>
    <description>Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device</description>
    <arm_group_label>TR BAND® plus SoftSeal®-STF hemostatic pad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SoftSeal®-STF hemostatic pad</intervention_name>
    <description>Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot</description>
    <arm_group_label>SoftSeal®-STF hemostatic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VascBand™ Hemostat</intervention_name>
    <description>The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.</description>
    <arm_group_label>VascBand™ Hemostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for an angiogram/PCI&#xD;
&#xD;
          -  Planned transradial approach&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of impaired dual perfusion to the hand when tested using Allen's test&#xD;
&#xD;
          -  Inaccessible radial arteries due to anatomic variations&#xD;
&#xD;
          -  Infection or other skin disorder at the puncture site&#xD;
&#xD;
          -  Undergoing an emergent or unplanned angiogram using the transradial approach&#xD;
&#xD;
          -  Evidence of severe cognitive impairment or inability to understand the study&#xD;
             procedures and answer follow-up questions&#xD;
&#xD;
          -  Known sensitivity or allergic reaction to materials in the study devices&#xD;
&#xD;
          -  Unwilling to participate in the study and follow all study-related procedures&#xD;
&#xD;
          -  Participating physician deems the subject to not be a good candidate&#xD;
&#xD;
          -  Inability to achieve radial access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad F Jan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiogram</keyword>
  <keyword>Hemostatic</keyword>
  <keyword>Activated clotting time</keyword>
  <keyword>Quality of Life</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

